Organizations are ramping up efforts to meet sustainability targets, despite geopolitical challenges
September 23, 2024 02:30 ET
|
Capgemini SE
Press contact:Victoire Grux Tel.: +33 6 04 52 16 55 Email: victoire.grux@capgemini.com Organizations are ramping up efforts to meet sustainability targets, despite geopolitical challenges 69% of...
Ageas announces its new three-year strategic plan: Elevate27
September 23, 2024 02:15 ET
|
Ageas
Regulated information • Inside information Ageas announces its new three-year strategic plan: Elevate27 Today, Ageas announces its next 3-year strategic plan, Elevate27, for the period 2025-2027. As...
Financing Update
September 23, 2024 02:00 ET
|
Vast Resources PLC
Vast Resources plc / Ticker: VAST / Index: AIM / Sector: Mining 23 September 2024 Vast Resources plc(‘Vast’ or the ‘Company’) Financing Update Vast Resources plc, the AIM-listed mining company,...
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
September 23, 2024 01:30 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving...
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024 01:00 ET
|
Teva Pharmaceutical Industries Ltd
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an...
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
September 22, 2024 10:00 ET
|
Black Diamond Therapeutics, Inc
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company...
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight
September 22, 2024 00:30 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 22, 2024 (GLOBE NEWSWIRE) -- Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight The graft versus host disease...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024 04:15 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
ROSEN, A LEADING LAW FIRM, Encourages CAE Inc. Investors to Inquire About Securities Class Action Investigation – CAE
September 20, 2024 19:13 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of CAE Inc....